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Pain is one of the most common symptoms in cancer patients. Opioids are widely prescribed
for this and other purposes. Properly used, they are safe, but they have serious and potentially
lethal side effects. Successful use of opioids to manage cancer pain requires adequate
knowledge about opioid pharmacology and equianalgesia for the purpose of both drug
rotation and route conversion. The aim of this study was to demonstrate variations in
equianalgesic ratios, as quoted in equianalgesic tables and various educational materials
widely available to practicing physicians. We surveyed commercially available educational
materials in package inserts, teaching materials provided by pharmaceutical companies, and
the Physicians’ Desk Reference for equianalgesic tables of commonly used opioids. We found
inconsistent and variable equianalgesic ratios recommended for both opioid rotation and
conversion. Multiple factors like inter- and intraindividual differences in opioid
pharmacology may influence the accuracy of dose calculations, as does the heterogeneity of
study design used to derive equianalgesic ratios. Equianalgesic tables should only serve as
a general guideline to estimate equivalent opioid doses. Clinical judgment should be used
and individual patient characteristics considered when applying any table. Professional
organizations and regulators should establish a rotation and conversion consensus
concerning opioid equianalgesic ratios. Systematic research on equianalgesic opioid dose
calculation is recommended to avoid adverse public health consequences of incorrect or
inappropriate dosing. Current information in equianalgesic tables is confusing for
physicians, and dangerous to the public. J Pain Symptom Manage 2009;38:409e417.
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Pain is present in 50% of those with
advanced cancer, and in more than 80% of
the terminally ill. It is the most feared and dis-
tressing symptom of advanced disease and re-
quires appropriate assessment and prompt
control.1e3 Opioids are the mainstay of cancer0885-3924/09/$esee front matter
doi:10.1016/j.jpainsymman.2009.06.004
410 Vol. 38 No. 3 September 2009Shaheen et al.pain treatment. Most patients achieve pain re-
lief with appropriate opioid dosing through
the use of published guidelines.4,5 Over the
last decade, opioid use in the United States
has more than doubled, according to the
International Narcotics Control Board of the
United Nations. Use of opioids requires
knowledge of opioid pharmacology, opioid ro-
tation (switching drugs), and opioid conver-
sion (changing routes of administration).
Unlike other medications, opioids have nei-
ther a ceiling effect nor uniform therapeutic
plasma levels. Consequently, individual titra-
tion to a clinically effective analgesic dose is
an accepted practice. Titration, however, often
is limited by opioid-induced side effects, com-
monly neurological or gastrointestinal toxicity.
In a patient with incomplete pain control or
troublesome side effects, opioid rotation or
route conversion, or both, may be necessary.6
There are now many opioids and opioid
formulations to choose from during this pro-
cess. The application of inappropriate relative
milligram potency ratios during opioid rota-
tion or conversion may have several serious
adverse consequences, including poor pain
control, excessive side effects, and death
from respiratory depression because of incor-
rect dosing.7e9
Physicians often consult the so-called equia-
nalgesic table before opioid rotation or
conversion to determine a new safe starting
dose appropriate for adequate pain control.
We have noted in clinical practice that various
published tables of this type have different
equivalence ratios. This raised questions about
the accuracy of current recommendations,
and their safety and efficacy in clinical
practice.
We surveyed commercially available and
educational materials for equianalgesic tables
in package inserts, the Physicians’ Desk Refer-
ence (PDR), teaching items provided by phar-
maceutical companies, and on Internet web
sites. Our primary objective was to examine
the variations in equianalgesic ratios, as
quoted in equianalgesic tables and various
educational materials. In addition, we planned
to assess the extent of such variations, and the
degree of inconsistency. We present the results
of our survey and also briefly discuss possible
explanations for the differences observed,
and pitfalls in the use of these tables.Methods
We searched the available equianalgesic ta-
bles using package inserts of commercially avail-
able, widely prescribed opioid formulations; for
example: Duragesic (Janssen Pharmaceutica,
Titusville, NJ), Dilaudid (Abbott Labs, North
Chicago, IL), Demerol (Sanofi-Aventis U.S.
LLC, Bridgewater, NJ), Dolphine (Roxane
Labs, Inc., Columbus, OH), Oramorph SR
(Roxane Labs, Inc., Columbus, OH), recom-
mendations from the PDR (Thomson PDR;
retrieved from http://www.pdr.net), product
information sections, and available teaching
materials provided by pharmaceutical compa-
nies intended to guide physician opioid pre-
scribing. We also sought online resources
designed to assist in opioid rotation and conver-
sion. We collated the information and summa-
rized it in three groups: 1) ratios available
from various pharmaceutical companies; 2)
data from the PDR; 3) data from the Internet.Results
Opioid Route Conversion
Table 1 lists the equianalgesic tables from
package inserts and teaching materials for
rotation and conversion of various commer-
cially available opioid products. Table 2
summarizes equianalgesic dosing recommen-
dations derived from the PDR for conversion
and rotation of commonly used opioids.
Some equianalgesic tables and equivalent ra-
tios were occasionally based on 24-hour opioid
requirements. Table 3 illustrates equianalgesic
tables for rotation and conversion available
online.
We found major variability in the route con-
version ratios for commonly used opioids
(Fig. 1). The conversion ratios of oral to paren-
teral morphine ranged from 3:1 to 2:1 (Tables
1 and 3) to 6:1 (Table 2). Those for oral to par-
enteral hydromorphone varied from 2:1 (Ta-
ble 1) to 5:1 (Tables 2 and 3). Oral to
parenteral methadone ratios varied from 2:1
(Table 1) to 10:1 and 4:1 (Table 3).
Opioid Drug Rotation
The tables also varied in the recommended
equivalence ratios for opioid rotation (Fig. 2).
The parenteral methadone to parenteral mor-
phine equianalgesic ratio varied from
Table 1
Equianalgesic Doses from Conversion Guides and Drug Inserts
Product
Pharmaceutical
Company
Source of Equianalgesic
Dosing
Oral Equianalgesic
Dose to Oral Morphine
Parenteral Equianalgesic
Dose to Parenteral
Morphine
Equianalgesic Dose
of Oral to Parenteral Route
Oxycodone Package insert (Purdue) 20:30
30:30b
20:40c
10:15a 30:15a
Duragesic Transdermal Janssen Package insert 25:60e134 mg/24 hours 25:10-22 mg/24 hours d
Dilaudid Abbott Labs Package insert 6.5e7.5:40e60 1.3e2:10 4:2 mg
Meperidine Dilaudid package insert 300e400:40e60 75e100:10 4:1
d
Dolphine HCl Roxane Labs, Inc. Package insert 2:1 mg
Levorphanol American Pain Society 4:30 (acute)
1:30 (chronic)
2:10 (acute)
1:10 (chronic)
4:2 (acute)
1:1 (chronic)
Levorphanol Dilaudid package insert 4:40e60 1:5
Morphine Alberta Hospice Palliative
Care Resource Manual
second edition (2001)d
2:1
Oramorph SR Roxane Labs, Inc. Package insert d d 3:1 mg
aDuragesic (Janssen) package insert.
bIASP Clinical Updates, Vol. 1, issue 2, July 1993, available at: http://www.iasp-pain.org/AM/AMTemplate.cfm?Section=Home&CONTENTID=7586&TEMPLATE=/CM/ContentDisplay.cfm. Accessed 2008.
cPalliative Medicine Handbook by lan N Back. Available at: http://book.pallcare.info/. Accessed 2008.
dAlberta Hospice Palliative Care Resource Manual. Available at: http://www.palliative.org/PC/Clinicalinfo/ACB%20PC%20resource%20manual.pdf. Accessed 2008.
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Table 2
Equianalgesic Ratios from the Physicians’ Desk Reference
Product
Source of Equianalgesic
Dosing
Equianalgesic Dose of
PO:Parenteral (mg)
Equianalgesic Dose
to 10 mg of IM
Morphine (mg)
Morphine sulfate PDR Electronic Library 40e60:10a d
Meperidine PDR Electronic Library 300e400:75e100a d
Hydromorphone HCl PDR Electronic Library 6.5e7.5:1.3e2a 1.3c
Methadone HCl PDR Electronic Library 10e20:10a 10c
Morphine PDR Electronic Library 60:10b d
Hydromorphone PDR Electronic Library 7.5:1.5b d
Methadone PDR Electronic Library 20:10b d
Codeine PDR Electronic Library 200:130b d
Oxycodone PDR Electronic Library 30:15b d
PO¼ oral; IM¼ intramuscular; SC¼ subcutaneous.
aTables from hydromorphone HCl product information section, parenteral¼ IM/SC.
bTables from fentanyl transdermal product information section, parenteral¼ IM.
cTables from hydromorphone HCl injection product information section, IM/SC route.
412 Vol. 38 No. 3 September 2009Shaheen et al.1:10e6.7:10 (Table 3) to 1:1 (Tables 1 and 2),
a 10-fold difference. The oral meperidine to
oral morphine ratios ranged from 6:1 (Table
1) to 10:1 (Table 3), based on 24-hour require-
ments. Modified-release oxycodone to modi-
fied-release morphine ratios ranged from 1:1
to 1:2 (Table 1). Similar variations were found
in the ratios between oral morphine and hydro-
morphone (40e60:6.5e7.5 to 10:2.5 [Tables 1
and3]). Also, ratios between transdermal fentan-
yl and both oral and parenteral morphine were
wide (Table 1: 25 mg:60 mg to 25 mg:134 mg
oral morphine and 25 mg:10 mg to 25 mg:22 mg
parenteral morphine).Discussion
When pain is not relieved adequately by an
opioid at a given dose, and limiting side effects
supervene, treatment with the same opioid by
an alternative route (conversion) or a differentTable 3
Online Opioid Analgesic Converter (www
Product
Equianalgesic Parenteral
Dose to 10 mg Parenteral
Morphinea (mg)
Morphine 10
Fentanyl 0.10
Meperidine 75
Hydromorphone 1.50
Methadone 2.0
Codeine 120
Oxycodone d
aEquianalgesic doses represent the total daily dose requirement.
bAcute short-term dosing.
cChronic dosing.opioid by the same route (rotation) is recom-
mended.10 In our experience and that of
others, route conversion and opioid rotation
are necessary in advanced cancer illness in
up to 40% of patients.11,12 This practice may
have adverse consequences, however, and
problems related to incorrect dosing. Multiple
considerations (Table 4) should be addressed
before both rotation and conversion to avoid
errors in applying any equianalgesic table
(even those which are accurate). Errors are
best avoided by: 1) knowledge of opioid phar-
macology, 2) awareness of the limits of equia-
nalgesic tables, 3) application of conversion/
rotation guidelines, and 4) tailoring opioid
use to individual patient characteristics and
response.
The equianalgesic dose is defined as that
dose at which two opioids (at steady-state) pro-
vide approximately the same pain relief. In the
research setting, this is usually standardized to
10 mg of parenteral morphine.7 Although no.globalrph.com/narcoticonv.htm)
Equianalgesic Oral Dose
to 10 mg Oral
Morphinea (mg)
Equianalgesic Oral
Dose to Parenteral
Dosea (mg)
10 10:3.3
d d
100 10:2.5
2.5 10:2
6.7b
1c
10 :1b
10 :2.5c
66.7 10:6
6.7 d
Fig. 1. Equianalgesic ranges for opioid route conversion.
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factors that influence opioid pharmacology or
exceptional clinical scenarios, they can cer-
tainly contribute to confusion because of vari-
ation in the ways equianalgesic doses are
illustrated, published, and applied.
Equianalgesic tables are derived largely from
single-dose studies, expert opinion, and studies
in noncancer patients. Cancer pain studies are
inherently difficult to conduct. A parallel study
design does not account for interpatient vari-
ability (e.g., age, gender, extent of disease,Fig. 2. Equianalgesic dose ratio ranges fprevious opioid experience, psychological fac-
tors, and so on). Stratification and randomiza-
tion may correct for variability, but reduce the
pool of potential study subjects. Although
a crossover design will reduce the required sam-
ple size and also lessen the effects of interpa-
tient (but not intrapatient) variability on study
outcomes, carry-over analgesia in 2 2 cross-
over designs may mask differences in efficacy
or toxicity (especially with longer-acting opi-
oids, such asmethadone). In the palliativemed-
icine cancer population, any study will beor opioid rotation to morphine.
Table 5
Problems and Pitfalls in Equianalgesic Tables
1. Failure to standardize a reference opioid
2. Failure to address bidirectional differences in
equianalgesia for certain opioids
3. Inclusion of wide range of doses in the equianalgesic
comparison
4. Use of equianalgesic tables as references for other tables
5. Equianalgesia between short- and long-acting opioids
not at steady-state
6. Equianalgesia between opioid formulations and opioid/
adjuvant combinations
7. Use of equianalgesia determined by single-dose studies
or acute pain
8. Equianalgesic doses in organ failure
9. Use of computations instead of clinical trial to
determine equianalgesic ratios
Table 4
Issues to Consider before Opioid Rotation
or Route Conversion
1. What are the indications for rotation/conversion?
2. Was the opioid given enough time to judge its efficacy
before rotation?
3. What are the alternatives to opioid rotation?
4. Can the goals of rotation be best achieved by using
a different route of administration (conversion) rather
than different opioid?
5. Are there any factors that would interfere or change
the equianalgesic dose?
6. Can equianalgesia change with dose?
7. Is the rotation taking place between opioids with
different half-lives?
8. Is the equianalgesic dose safe?
9. Is the pain syndrome responsive to the new opioid?
10. Has the patient been treated with opioids for a short
period of time or chronically?
414 Vol. 38 No. 3 September 2009Shaheen et al.adversely affected byhighdropout rates and var-
iation in pain from disease progression. Even
with sound methodology and adequate patient
number, other factors, such as drug tolerance
and hypersensitivity, are impossible to totally
eliminate.
Evidence of the dangers of inconsistent equi-
analgesic ratios is sparse. This is because opioid
clinical trials are often performed in highly
selected patients, rarely blinded, seldom pow-
ered to adequately detect adverse events, and
usually conducted by pain specialists familiar
with proper opioid-dosing strategies. In addi-
tion, trials with the sole purpose of detecting po-
tentially fatal or serious side effects would be
marred by ethical concerns. Recent evidence
suggests that opioid-related deaths are increas-
ing exponentially.13 This is inadequately
explained by a rise in drug abuse, and moreTable 6
Clinical Guidelines for Opioid Rou
1. Rotation secondary to toxicity requires a dose 30%e50% lower
of incomplete analgesic cross-tolerance.22
2. Rotation secondary to uncontrolled pain requires equianalgesic
3. Thirty percent on opioids need an alternative route,24 as in sev
4. Before rotation because of toxicity, consider treating side effect
adjuvant analgesics.25
5. Consider pharmacokinetic change with age, comorbid conditio
starting or titrating opioids.
6. Opioids that are partial agonists have less analgesia per dose in
high intrinsic efficacy (e.g., methadone);26,27 therefore, equiana
7. Rotation between short- and long-acting opioids must be done
8. Rotation in the setting of organ dysfunction is potentially disast
tables.29,30
9. Opioids may worsen intestinal colic. Dexamethasone, glycopyrro
10. Opioid-induced toxicity takes time to resolve. Persistent toxicity
opioid and not the new opioid.
11. Rotating to a new opioid before reaching steady-state of the firsclosely correlated with an increase in the num-
ber of opioid prescriptions.13 Although these
trends cannot be proved to relate to opioid rota-
tion or conversion, they underscore the
potentially lethal effects of opioids when incor-
rectly or inappropriately dosed. This is given
credence by a trial that compared methadone
and diamorphine in cancer patients, which
was prematurely terminated because of higher
mortality in themethadonegroup.14 Potentially
lethal opioid side effects during rotation have
been identified in a number of reports.15e17
In one study of 50 patients with severe cancer
pain, six developed respiratory depression on
methadone after rotation from hydromor-
phone.15 In a case report, a patient developed
respiratory depression after rotation from hy-
dromorphone.16 In another report, one patient
onmodified-releasemorphine developed respi-
ratory depression when rotated to transdermal
fentanyl.17 Lethal complications appearte Conversion and Rotation
than the equivalent dose of the second opioid because
doses.23
ere nausea or mucositis.
s, lowering opioid dose (if pain is controlled), and use of
ns, gender, interacting medications, and organ failure in
crement at higher doses than full agonists or opioids with
lgesic ratios will change with dose.
carefully to avoid withdrawal or overdosing.28
rous despite the recommended doses from equianalgesic
late, or octreotide are better for such pains.31
after rotation may be because of slow clearance of the first
t opioid is pharmacologically meaningless.
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cialists. The literature concerning opioid-re-
lated mortality or potentially lethal
complications in clinical practice are dispropor-
tionably sparse relative to the volume of opioids
now prescribed.
Current equianalgesic tables, therefore,
pose several problems:
1. Morphine is the widely accepted proto-
type opioid analgesic, but some equianal-
gesic tables confusingly used opioids
other than morphine as the reference
point.
2. Variable equivalence ranges, within or be-
tween different equianalgesic tables,
likely result in confusion and inaccurate
opioid conversion and rotation. Calculat-
ing the median equivalence values based
on them may be inaccurate.
3. Computations, rather than data from
clinical trials, are sometimes used to esti-
mate or infer the potency ratios between
opioids. Such derived ratios are devoid of
clinical context and might be grossly
inaccurate.
4. Another problem is how to provide calcu-
lated equivalents between an opioid and
a compounded analgesic that contains
an opioid and an adjuvant analgesic (usu-
ally a nonsteroidal anti-inflammatory
drug). The latter formulations cannot
be compared similarly to a single opioid
because the adjuvant contributes signifi-
cantly to pain relief.
Originally, we intended to assess only those
tables that used morphine as the reference
opioid. This was impossible, as some use other
opioids (and varied doses) as the reference
opioid. Our survey did not include all pub-
lished tables, nor was it intended to; however,
it documents the wide range of values pub-
lished in commercially available opioid equia-
nalgesic tables, and illustrates the dangerous
inconsistency in recommended doses for
both opioid drug rotation and route conver-
sion. Consensus about opioid equianalgesic ra-
tios have been previously published.18,19 These
guidelines did not involve feedback from other
specialties (such as primary care physicians) in-
creasingly involved in cancer pain treatment.
In a survey among nursing staff, 75% lacked
adequate knowledge about equianalgesicratios.20 In another study, 33% of nurses on
oncology wards were unable to calculate equi-
analgesic doses, despite having access to equia-
nalgesic tables.21 Although nurses are not
usually primary prescribers, these findings il-
lustrate problems in using any of the equianal-
gesic tables and conversion/rotation
guidelines. This problem is compounded by
the differences we found between tables. For
example, a conversion of 20 mg hydromor-
phone from the parenteral to oral route (as of-
ten happens before patients are discharged
home) using Table 1 yields 40 mg oral hydro-
morphone, but using Table 3, results in
a 100 mg oral equivalent. This is pharmacolog-
ically important and clinically dangerous. It is
possible for two physicians working in the
same clinical unit to use different tables for
conversion or rotation and arrive at markedly
different conclusions, and risk serious toxicity.
Physicians would likely prefer a single practical
table outlining the equivalents of commonly
used opioids and singular conversion ratios.
This is particularly the case for those who pre-
scribe opioids infrequently or are not pain
specialists. The benefits would include conve-
nience, simplicity, and easy access to the de-
sired comparison information. As consensus
tables are lacking, those available are useful
only as quick references at the time of opioid
rotation or conversion.
Most of the tables we reviewed include com-
monly used opioids. Nevertheless, they must
be used cautiously because they do not address
critical individual factors. Gender differences
and organ dysfunction, bidirectional differ-
ences in equivalence with certain opioids,
drug interactions, and large inter- and intrain-
dividual differences in pharmacokinetics and
pharmacodynamics all may alter equianalgesia.
Prescribers must recognize the limitations of
existing equianalgesic tables, and proceed
with rotation and/or conversion only after
a comprehensive assessment that includes
patient characteristics and the pain syndrome.
The goal of this study was to report inconsis-
tencies among available equianalgesic tables
and other educational materials, not to evalu-
ate them for accuracy or superiority. In our
experience, numerous problems and pitfalls
in equianalgesic tables exist (Table 5). Varia-
tions in equianalgesic dosing will likely persist
secondary to the heterogeneous patient
416 Vol. 38 No. 3 September 2009Shaheen et al.population in which they are prescribed, and
a gold standard table applicable in all clinical
situations appears unrealistic. Nevertheless,
a consistent approach should be achieved by
establishing guidelines from expert consensus
groups to assist physicians in selecting the
most appropriate equivalences, which may
then be modified according to the clinical con-
text. Clinical guidelines to approach opioid
conversion and rotation based on our experi-
ence (and that of others) are outlined in Table
6.22e31 The current situation is unacceptable,
and is a major public health concern.Conclusions
We have identified wide and clinically
important differences in published opioid
equianalgesic ratios. The information con-
tained in equianalgesic tables and other educa-
tional materials is confusing to physicians and
dangerous to patients. Equianalgesic tables
should serve to estimate doses that are safe if
applied to the general population. This should
represent a first step in the clinical decision
made on opioid rotation or conversion. Other
considerations should include indications for
rotation, drug-drug interactions, alternatives
to rotation before applying these tables, and
host factors that interfere with analgesia. In ad-
dition, better presentation of information, sep-
aration of ratios for acute and chronic dosing,
and mandatory education for those licensed to
prescribe opioids and treat cancer pain will
help alleviate any confusion. A consensus of
multispecialty expert opinion to establish cor-
rect and safe equianalgesic dosing for opioid
conversion and rotation is recommended.
This will maintain quality care without jeopard-
izing patient safety.References
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